Kornimate/medical-research-clean huggingface dataset:
characterization of new human models of non-histaminergic itch and their interaction with the trpm8 receptor

Conditions: Itch

Summary: in this experiment the investigators would like to assess if papain induces an itch sensation comparable to the itch sensation induced by cowhage and to confirm that the mechanism of action of papain follows the non-histaminergic pathway.


Eligibility criteria:
inclusion criteria: * healthy men and women * 18-60 years * speak and understand english exclusion criteria: * pregnancy or lactation * drug addiction defined as any use of cannabis, opioids or other addictive drugs * previous or current history of neurological, dermatological, immunological musculoskeletal, cardiac disorder or mental illnesses that may affect the results (e.g. neuropathy, muscular pain in the upper extremities, etc.). * lack of ability to cooperate * current use of medications that may affect the trial such as antihistamines, antipsychotics and pain killers, as well as systemic or topical steroids. * skin diseases * moles, scars or tattoos in the area to be treated or tested. * hypersensitivity to papaya and mango fruit, cashew nuts, rubber latex * consumption of alcohol or painkillers 24 hours before the study days and between these * acute or chronic pain * participation in other trials within 1 week of study entry (4 weeks in the case of pharmaceutical trials)
cardiomems hf system post approval study

Conditions: Heart Failure; Left-Sided Heart Failure; Congestive Heart Failure

Summary: the purpose of the cardiomems hf system post approval study (pas) is to evaluate the use of the cardiomems hf system in patients with nyha class iii heart failure in a commercial setting.

the primary objective of this study is to demonstrate the safety and to report clinical performance of the cardiomems™ hf system in real world setting. prospective, non-randomized, open-label, multi-center, post-market study designed to characterize the use of the cardiomems™ hf system in a real-world setting in the us; n=1200. it is the condition of approval study.

Eligibility criteria:
inclusion criteria: * diagnosis of nyha class iii heart failure * at least 1 heart failure hospitalization within previous 12 months * patients with reduced lvef heart failure should be receiving a beta blocker for 3 months and an ace-i or arb for one month unless in the investigator's opinion, the patient is intolerant to beta blockers, ace-i or arb * bmi ≤ 35. patients with bmi \>35 will require their chest circumference to be measured at the axillary level. if \> 65 inches the patient will not be eligible for the study. * pulmonary artery branch diameter ≥ 7mm - (implant target artery - assessed during the right heart catheterization) exclusion criteria: * active infection * history of recurrent (\> 1) pulmonary embolism or deep vein thrombosis * inability to tolerate a right heart catheterization * a major cardiovascular event (e.g., myocardial infarction, open heart surgery, stroke, etc.) within previous 2 months * cardiac resynchronization device (crt) implanted within previous 3 months * glomerular filtration rate (gfr) \< 25 ml/min (obtained within 2 weeks of implant) who are non-responsive to diuretic therapy or who are on chronic renal dialysis * congenital heart disease or mechanical right heart valve * likely to undergo heart transplantation or vad within the next 6 months * known coagulation disorders * hypersensitivity or allergy to aspirin, and/or clopidogrel

Keywords: pulmonary artery pressure monitoring implantable hemodynamic monitor
medication repurposing to stop cognitive decline in dementia

Conditions: Alzheimer Dementia; Dementia Disorders

Summary: dementia creates a great personal and societal burden and there are currently no treatments to stop memory loss. many patients with dementia take medications to treat other conditions, e.g. high blood pressure and cholesterol. some of these medications may have central effects on the pathophysiological processes leading to dementia. medication repurposing is a cost and time-effective way to discover new treatments. swedish registers are a unique tool to detect medication candidates for repurposing. the swedish dementia registry (svedem) has \>100000 patients and ca. 144000 measures of cognition over time (measured with the mini-mental state examination-mmse), making it perfect to examine whether certain medications are associated with less cognitive decline in patients with dementia. cholesterol and kidney function affect treatment and cognition and are available for 25000 patients. the investigators propose a study combining traditional cohort studies and newer artificial intelligence (machine learning) techniques to detect medications associated with slower cognitive decline in patients from svedem. the investigators will test pre-specified hypotheses since the investigators suspect specific medications are better candidates to prevent cognitive decline, but the investigators will also let the machine learning algorithms explore the data to find associations that the investigators do not suspect in advance. finally, the candidate medications will be tested in animal and cellular models to determine the mechanisms of their effects.


Eligibility criteria:
inclusion criteria: all patients with dementia registered in svedem. exclusion criteria: lack of swedish personal identification number or coordination number.

Keywords: medication repurposing cognitive decline dementia mini-mental state examination
modulation of fear extinction processes using transcranial electrical stimulation

Conditions: Stress Related Disorder; Anxiety

Summary: the aim of this study is to examine the effects of transcranial electrical stimulation on processes associated with fear extinction in healthy humans.

research links the processes of fear conditioning and extinction to the treatment of anxiety and stress-related disorders. moreover, considerable translational research examines the neural correlates of these processes. however, virtually no research in humans manipulates neural correlates of these processes, which limits basic-clinical integration. the present study aimed to use transcranial electrical stimulation (tes) to modulate processes associated with fear extinction in order to assess the potential utility of tes in enhancing exposure-based treatment. to this end, healthy participants underwent a three-day fear conditioning and extinction paradigm. participants were randomly assigned into 3 groups, differing in terms of tes applied during the extinction learning phase (day 2) and targeting the medial prefrontal cortex: 1) direct current (dc) stimulation, aimed at enhancing extinction learning; 2) alternate current (ac) stimulation, aimed at interfering with reconsolidation of the fear memory activated during the extinction phase; and 3) sham stimulation. the outcome measures (outlined next) involve the assessment of extinction recall during a test phase (day 3). successful modulation of extinction learning by tes would be reflected in enhanced extinction recall.

Eligibility criteria:
inclusion criteria: exclusion criteria: * self-reported major psychiatric condition * screening specific for electrical stimulation (psychotropic medication, metal implants in head, epilepsy or seizure history)
dpp-4 inhibitors and acute myocardial infarction:effects on platelet function

Conditions: Platelet Aggregation During Acute Myocardial Infarction

Summary: cardiovascular events are the main cause of mortality in diabetic patients ,on the other hand,during an acute myocardial infarction(ami),hyperglycemia increases mortality and is related to different pathophysiologic processes. more important evidence regarding the effect of glycemic control on ami patients prognosis is contradictory,and the potential benefits of dipeptidyl peptidase-4 inhibitors(dpp4-i) in this setting is unknown. the aim of this study is to assess the presence of pleiotropic effects of dpp4-i(sitagliptin or saxagliptin) and their relationship with glycemic control during in-hospital phase of ami.

randomized clinical trial,double-blinded,placebo-controlled, in a single center, to assess the influence of dpp4-i on platelet aggregability in type 2 diabetic patients with acute myocardial infarction in use of dual anti platelet therapy (dapt) . others exploratory analysis include:glycemic control ,infarct size,genetic analysis and cholesterol metabolism. after giving signed informed consent,eligible subjects will be randomly allocated to receive saxagliptin or placebo, in the first 48 hours (+-24) after the beginning of an ami. the investigator and subjects will be blinded to trial treatment,and a person not involved in trial conduct will prepare the doses of study drug.the doses will be administered by mouth,in a once daily basis by the investigator. blood samples will be collected by the investigator according to pre-specified outcomes and time frames. evaluation of glycemic control by cgm will be carried out by the investigator,including insert and withdrawal of the device. treatment of the acute event,(ami) will be done according to routine procedures from coronary care unit. serious adverse event report taking into consideration all-cause mortality, cardiovascular mortality, hospitalization for heart failure and pancreatitis, will be done according to presence of these events.

Eligibility criteria:
inclusion criteria: * previous diagnosis of type 2 diabetes mellitus,with treatment including insulin and/or oral antidiabetic agent; * subjects without previous diagnosis of diabetes,but hba1c admission \>= 6,5% during current hospital-stay * ami with or without st-elevation; * use of double antiplatelet therapy; * signed informed consent term exclusion criteria: * gfr \<30 ml/min; * use of dpp4 inhibitors or glucagon- like peptide-1(glp1) analogue in the past 6 months; * use of strong inhibitors of cytochrome p450(cyp3a4/5) ou glucocorticoids; * severe systemic decompensation requiring insulin infusion; * killip classification of myocardial infarction grade \>2; * previous history of pancreatitis

Keywords: diabetes mellitus platelet function testing acute coronary syndromes saxagliptin sitagliptin dpp-4 inhibitors
engaging sexual and gender minority cigarette smokers into social media-based treatment

Conditions: Smoking Cessation; Nicotine Dependence; Tobacco Use; Cigarette Smoking

Summary: this research study will evaluate the preliminary efficacy of pride posts plus, a social media-based smoking cessation treatment. a pilot randomized trial (n=120) will compare pride posts plus, which includes a gamification element, to pride posts (without gamification) and to a usual care treatment. participants will be adults who smoke, identify as sexual or gender minorities, and use facebook. the primary outcome will be biochemically verified 7-day abstinence from smoking at 3 and 6 months. secondary outcomes will be treatment engagement, a quit attempt (y/n), and thoughts about tobacco abstinence at 3 and 6 mos.

participants (n=136) will be randomized to one of three conditions: (1) pride posts, a facebook-delivered smoking cessation intervention (including daily posts, and weekly live group sessions, tailored to sexual and gender minority (sgm) adults; (2) pride posts plus, the facebook-delivered smoking cessation intervention plus a gamification element, or (2) a usual care condition which includes referral to smokefree.gov, a federally-developed web-based intervention which includes similar digital treatment elements. all participants will have access to up to six months of nicotine replacement therapy (nrt). assessments will occur at baseline, 3, and 6 months follow-up. assessments will include measures on smoking, thoughts about abstinence, and sgm identity experiences. all participants who report no past 7-day smoking will be asked to provide biochemical verification of smoking status using a portable carbon monoxide measurement tool. all intervention and assessment procedures will be conducted digitally.

Eligibility criteria:
inclusion criteria: * daily smoker * self-identify as sexual and/or gender minority * interested in quitting in next 6 months * 6 months of facebook experience * english-speaking exclusion criteria: * contraindications to nicotine replacement therapy

Keywords: smoking social media lgbt sexual and gender minority nicotine replacement therapy digital interventions
management of threatened preterm labor by cervical length-based approach or conventional approach

Conditions: Preterm Delivery Within 7 Day After Admission

Summary: to compare the effectiveness of treatment of threatened preterm labor between transvaginal cervical length-based approach and conventional approach (per vaginal examination)


Eligibility criteria:
inclusion criteria: * pregnant with symptoms of threatened preterm labor which refer to regular uterine contractions at least 1 time in every 10 minutes and persist for 30 minute without cervical dilatation or cervical dilation ≤ 1 cm and \< 80% of effacement. * age ≥ 18 years * singleton pregnancy * 24 0/7 - 33 6/7 weeks of gestation * uneventful antenatal care or low-risk pregnancies exclusion criteria: * the definitive diagnosis of true labor * proceed to the active phase of labor * age \< 18 years * multiple pregnancies * \< 24 or ≥ 34 weeks of gestation * fetal chromosomal or structural abnormalities * abnormal fetal growth * abnormal amniotic fluid * evidence of placenta previa * significant vaginal bleeding that cannot be ruled out placenta previa * evidence of rupture of membranes * evidence of intrauterine infection * evidence of uterine malformation * evidence of lethal fetal malformation * unable to communicate or understand the information of the study
venek: healing in different vein harvesting methods during aortocoronary coronary artery bypass graft surgery (cabg)

Conditions: Coronary Artery Disease

Summary: the venek trial is a randomized, prospective trial to compare economic parameters, quality of life and wound healing after endoscopic vein harvesting versus open vein harvesting.

the venek trial is a randomized, prospective trial to compare economic parameters, quality of life and wound healing after endoscopic vein harvesting versus open vein harvesting.

Eligibility criteria:
inclusion criteria: * age over 60 years * admission at herzzentrum dresden - herzchirurgie for bypass-operation (op) with planned veinectomy * eligibility for different modes of planned intervention according to study protocol * signed patient informed consent exclusion criteria: * varicose crural veins * emergency patients * combined operational procedures * preoperative complete immobilization

Keywords: cardiovascular system veins saphenous vein
handgrip strengthening exercise in treatment of the patients with primary sub-acromial impingement syndrome

Conditions: Impingement Syndrome, Shoulder

Summary: this study aims to investigate the relative effect of handgrip strengthening exercise in improving function, pain, strength, and active range of motion (arom) of the shoulder among patients with primary sub-acromial impingement syndrome (sais).

the current study is a single-blind randomized clinical trial to investigate the effectiveness of handgrip strengthening exercise in the treatment of patients with primary subacromial impingement syndrome. the randomization process will be based on concealed envelop picked up by participants.the patient will be conveniently recruited from the ministry of health hospitals in jeddah.the patient who will meet the inclusion criteria; they will sign the consent form. the baseline data will be collected. the assessment will be carried out at the baseline, 4 weeks and 8 weeks; end of the treatment program; by the same blinded examiner for each patient and consist of the following instrument: disabilities of arm, shoulder \& hand (dash questionnaire), visual analog scale (vas), hand-held dynamometer (hhd), and smartphone clinometer.

Eligibility criteria:
inclusion criteria: * willing to comply with all study procedures and be available for the duration of the study * aged 18 to 45 * diagnosed by their referring physician with subacromial impingement syndrome and has a positive impingement \& rotator cuff test * pain intensity between 3 to 8 in vas exclusion criteria: * history of shoulder fracture or dislocation, osteophytes, and labral tear. * history of cardiac, neurological or musculoskeletal disease that precludes the ability to perform the exercise in the upper extremity. * treatment with another intervention. * hand or forearm dysfunction * rheumatoid disease * diabetic * history of shoulder, cervical, and thoracic surgery * pregnancy * malignancy * symptoms for more than 1 year * bilateral sais
transcranial direct current stimulation acute stroke walking

Conditions: Acute Stroke

Summary: 16 acute stroke patients will be split into 2 groups. one group will receive the real treatment (anodal tdcs) and one group sham. subjects will receive, in addition to conventional rehabilitation, 2ma for 20 mins of their attributed tdcs, 5 times a week. evaluations will take place before the first stimulation period (48h post stroke), after 1, 2, 3 and 4 weeks. the evaluations are the four square step test, the berg balance scale, the postural assessment scale for stroke, the trunk impairment scale, the time up \& go and the 10 meter walking test.


Eligibility criteria:
inclusion criteria: * first ever stroke * motor or sensory deficit * understands and follows orders * signed inform consent exclusion criteria: • one yes on the medium and high risk sections of the tsst (bornheim et al.,2019)

Keywords: acute stroke tdcs anodal balance walking
effects of exposure to biomass-burning air pollution on lung function, heart rate variability and inflammatory markers in sugarcane workers

Conditions: Lung Function; Heart Rate Variability; Oxidative Stress; Systemic Inflammatory Response

Summary: introduction: non-mechanized sugar cane harvesting preceded by burning, an important and prevalent professional activity of agribusiness segment of the brazilian economy, exposes workers and people of neighboring towns to high concentrations of pollutants and, therefore, potentially several risks to health hazards. objectives: assessing cardiopulmonary impacts and inflammatory markers in sugarcane workers and volunteers from a nearby town in non-harvest and harvest periods.


Eligibility criteria:
inclusion criteria: * the criteria for inclusion in the study were: age between 20 and 40 years, male gender and being non-smokers (or former-smokers for at least a year and a smoking history of less than 20 pack-years). exclusion criteria: * exclusion criteria were history of cardiovascular or respiratory disease, the use of bronchodilator, non-steroidal anti-inflammatory drugs, anticoagulants or antiplatelet drugs and statins.
glycyphagus domesticus allergen extract. determination of the in vivo biological activity in histamine equivalent units (hep).

Conditions: Rhinitis, Allergic, Seasonal; Conjunctivitis, Allergic

Summary: the main purpose of the trial is to prove the therapeutic value of the product and enable an effective and safe dosage schedule to be recommended

the objective of this study is to determine the biologic activity of a glycyphagus domesticus allergen extract in histamine equivalent prick (hep) units, in order to be used as in-house reference preparation (ihrp). the skin testing procedure, based on the nordic guidelines is the reference method for the biological calibration of in-house reference preparations (ihrp). the method is not intended for routine testing of allergen extracts. the use of this procedure is the basis for the definition of biological activity units: "the activity of an allergen extract is 10,000 biological units (bu) per ml (10 hep per ml), when the extract provokes an specific skin reaction in the median sensitive patient with a wheal of the same size as a wheal provoked by a positive reference solution consisting of histamine 54.3 mmol/l (for example histamine dihydrochloride 10 mg/ml), when both solutions are administrated using the same technique (prick testing) on at least 20 individuals who are clinically allergic and cutaneously reactive to the allergen concerned".

Eligibility criteria:
subject inclusion criteria: 1. a documented positive case history with inhalation allergy (rhinitis and/or rhinoconjunctivitis and/or asthma) related to glycyphagus domesticus. 2. positive skin prick test with an available preparation of the same allergen extract (a wheal major diameter of at least 3 mm) and/or a positive test for specific ige. 3. mean of the areas of the wheals provoked by histamine dihydrochloride (10 mg/ml) ≥ 7 mm2. 4. age ≥ 18 years and ≤ 50 years 5. subject can be male or female 6. subject must be capable of providing written informed consent subject exclusion criteria: 1. subjects should not be excluded due to low or high sensitivity to glycyphagus domesticus. 2. immunotherapy in the past 2 years with an allergen preparation known to interfere with the allergens to be tested. 3. use of drugs that may interfere with the skin reactions. 4. pregnancy, dermographism, atopic dermatitis (locally at the test site), urticaria. 5. any disease which prohibits the use of adrenaline (hyperthyroidism, arterial hypertension, cardiopathy, etc.) 6. lack of cooperation which may interfere with the study, or subjects with severe psychiatric, psychological or neurological disorders.

Keywords: allergen extract standardization